• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Alpha Teknova Inc. (Amendment)

    2/14/24 4:06:12 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $TKNO alert in real time by email
    SC 13G/A 1 tm246170d1_sc13ga.htm SC 13G/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.2)*

     

      Alpha Teknova, Inc.  
      (Name of Issuer)  
         
      Common Stock, par value $0.00001  
      (Title of Class of Securities)  
         
      02080L102  
      (CUSIP Number)  
         
      December 31, 2023  
      (Date of Event Which Requires Filing of this Statement)  

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

    ¨ Rule 13d-1(c)

    x Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.  02080L102

     

    1.  

    Name of Reporting Persons

     

    Telegraph Hill Partners IV, L.P.

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3.  

    SEC Use Only

     

    4.  

    Citizenship or Place of Organization

     

    State of Delaware

    Number of Shares

    Beneficially Owned

    By Each Reporting

    Person With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    25,620,792 (1)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    25,620,792 (1)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

    25,620,792 (1)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

    62.9%(1)(2)

    12.  

    Type of Reporting Person (See Instructions)

    PN

             
    (1)Includes (i) 21,859,660 shares of common stock held by Telegraph Hill Partners IV, L.P. and (ii) 3,761,132 shares of common stock held by THP IV Affiliates Fund, LLC.
    (2)Consists of 40,727,780 shares of Common Stock of the Issuer outstanding on November 9, 2023, based on information publicly disclosed by the Issuer.

     

     

     

     

     

    CUSIP No.  02080L102

     

    1.  

    Name of Reporting Persons

     

    THP IV Affiliates Fund, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3.  

    SEC Use Only

     

    4.  

    Citizenship or Place of Organization

     

    State of Delaware

    Number of Shares

    Beneficially Owned

    By Each Reporting

    Person With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    25,620,792 (1)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    25,620,792 (1)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

    25,620,792 (1)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

    62.9%(1)(2)

    12.  

    Type of Reporting Person (See Instructions)

    PN

             
    (1)Includes (i) 21,859,660 shares of common stock held by Telegraph Hill Partners IV, L.P. and (ii) 3,761,132 shares of common stock held by THP IV Affiliates Fund, LLC.
    (2)Consists of 40,727,780 shares of Common Stock of the Issuer outstanding on November 9, 2023, based on information publicly disclosed by the Issuer.

     

     

     

     

     

    CUSIP No.  02080L102

     

    1.  

    Name of Reporting Persons

     

    Telegraph Hill Partners IV Investment Management, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3.  

    SEC Use Only

     

    4.  

    Citizenship or Place of Organization

     

    State of Delaware

    Number of Shares

    Beneficially Owned

    By Each Reporting

    Person With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    25,620,792 (1)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    25,620,792 (1)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

    25,620,792 (1)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

    62.9%(1)(2)

    12.  

    Type of Reporting Person (See Instructions)

    PN

             
    (1)Includes (i) 21,859,660 shares of common stock held by Telegraph Hill Partners IV, L.P. and (ii) 3,761,132 shares of common stock held by THP IV Affiliates Fund, LLC.
    (2)Consists of 40,727,780 shares of Common Stock of the Issuer outstanding on November 9, 2023, based on information publicly disclosed by the Issuer.

     

     

     

     

     

    CUSIP No.  02080L102

     

    1.  

    Name of Reporting Persons

     

    Telegraph Hill Partners Management Company, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3.  

    SEC Use Only

     

    4.  

    Citizenship or Place of Organization

     

    State of Delaware

    Number of Shares

    Beneficially Owned

    By Each Reporting

    Person With:

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    25,620,792 (1)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    25,620,792 (1)

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

    25,620,792 (1)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

    62.9%(1)(2)

    12.  

    Type of Reporting Person (See Instructions)

    PN

             
    (1)Includes (i) 21,859,660 shares of common stock held by Telegraph Hill Partners IV, L.P. and (ii) 3,761,132 shares of common stock held by THP IV Affiliates Fund, LLC.
    (2)Consists of 40,727,780 shares of Common Stock of the Issuer outstanding on November 9, 2023, based on information publicly disclosed by the Issuer.

     

     

     

     

    Item 1(a). Name of Issuer
       
      Alpha Teknova, Inc. (the “Issuer”)
       
    Item 1(b). Address of the Issuer’s Principal Executive Offices
       
      2290 Bert Drive, Hollister, California 95023
       
    Item 2(a). Names of Persons Filing
       
      This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

      (i) Telegraph Hill Partners IV, L.P.
         
      (ii) THP IV Affiliates Fund, LLC
         
      (iii) Telegraph Hill Partners IV Investment Management, LLC
         
      (iv) Telegraph Hill Partners Management Company, LLC

     

    Item 2(b). Address of the Principal Business Office, or if none, Residence:
       
      The address of the principal business and principal office of each of the Reporting Persons is 360 Post Street, Suite 601, San Francisco, California 94108.
       
    Item 2(c). Citizenship

     

      (i) Telegraph Hill Partners IV, L.P. is a Delaware limited partnership.
         
      (ii) THP IV Affiliates Fund, LLC is a Delaware limited liability company.
         
      (iii) Telegraph Hill Partners IV Investment Management, LLC is a Delaware limited liability company.
         
      (iv) Telegraph Hill Partners Management Company, LLC is a Delaware limited liability company.

     

    Item 2(d). Title of Class of Securities
       
      Common stock, par value $0.00001 per share
       

    Item 2(e). CUSIP Number
       
      02080L102

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

      Not applicable.

     

     

     

     

    Item 4.

    Ownership

     

    (a)       Amount Beneficially Owned:

     

    Telegraph Hill Partners IV, L.P.

     

    14,941,823 shares of common stock are held of record by Telegraph Hill Partners IV, L.P. (“THP IV”). Telegraph Hill Partners IV Investment Management, LLC (“THP IM”) is the general partner of THP IV. Telegraph Hill Partners Management Company, LLC (“THPMC”) is the manager of THP IM.

     

    THP IV Affiliates Fund, LLC

     

    2,570,862 shares of common stock are held of record by THP IV Affiliates Fund, LLC (“THP IV AFF”). THP IM is the manager of THP IV AFF. THPMC is the manager of THP IM.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable.
       
     Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group
       
      See Exhibit B.
       
    Item 9. Notice of Dissolution of Group
       
      Not applicable.
       
    Item 10. Certification
       
      By signing below each of the undersigned certifies that, to the best of its or his knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DATE: February 14, 2024

     

     

    Telegraph Hill Partners IV, L.P.

    By: Telegraph Hill Partners IV Investment Management, LLC

    Its: General Partner

    By: Telegraph Hill Partners Management Company LLC

    Its: Manager

     

      By: /s/ Rob Hart
        Rob Hart
        Partner

     

     

    THP IV Affiliates Fund, LLC

    By: Telegraph Hill Partners IV Investment Management, LLC

    Its: Manager

    By: Telegraph Hill Partners Management Company LLC

    Its: Manager

     

      By: /s/ Rob Hart
        Rob Hart
        Partner

     

     

    Telegraph Hill Partners IV Investment Management, LLC

    By: Telegraph Hill Partners Management Company LLC

    Its: Manager

     

      By: /s/ Rob Hart
        Rob Hart
        Partner

     

     

    Telegraph Hill Partners Management Company, LLC

     

      By: /s/ Rob Hart
        Rob Hart
        Partner

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations

    (See 18 U.S.C. 1001)

     

     

     

     

    EXHIBIT INDEX

         
    Exhibit
    Number
      Description
    A   Joint Filing Agreement (incorporated by reference to Exhibit A to the Schedule 13G/A filed on October 6, 2023).
       
    B   Group disclosure (incorporated by reference to Exhibit B to the Schedule 13G/A filed on October 6, 2023).

     

     

     

    Get the next $TKNO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TKNO

    DatePrice TargetRatingAnalyst
    7/22/2025$8.00Overweight
    Stephens
    2/10/2025$12.00Buy
    Craig Hallum
    3/12/2024Buy → Neutral
    BTIG Research
    7/20/2021Overweight
    Stephens
    7/20/2021$27.00Overweight
    Stephens & Co.
    7/20/2021Outperform
    Cowen & Co.
    7/20/2021$26.00Buy
    BTIG
    More analyst ratings

    $TKNO
    SEC Filings

    View All

    SEC Form 10-Q filed by Alpha Teknova Inc.

    10-Q - Alpha Teknova, Inc. (0001850902) (Filer)

    8/8/25 4:07:19 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Alpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Alpha Teknova, Inc. (0001850902) (Filer)

    8/7/25 4:07:41 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form EFFECT filed by Alpha Teknova Inc.

    EFFECT - Alpha Teknova, Inc. (0001850902) (Filer)

    7/17/25 12:15:12 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Demski Martha J sold $40,512 worth of shares (8,000 units at $5.06), decreasing direct ownership by 40% to 12,000 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/1/25 4:59:45 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form 4 filed by Director Vos Alexander

    4/A - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/1/25 4:29:28 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form 4 filed by Director Robertson Brett

    4/A - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/1/25 4:29:06 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens resumed coverage on Alpha Teknova with a new price target

    Stephens resumed coverage of Alpha Teknova with a rating of Overweight and set a new price target of $8.00

    7/22/25 7:51:11 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Craig Hallum initiated coverage on Alpha Teknova with a new price target

    Craig Hallum initiated coverage of Alpha Teknova with a rating of Buy and set a new price target of $12.00

    2/10/25 8:24:48 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Alpha Teknova downgraded by BTIG Research

    BTIG Research downgraded Alpha Teknova from Buy to Neutral

    3/12/24 7:34:27 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Teknova Reports Second Quarter 2025 Financial Results

    Second quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025. "Despite continued uncertainty in the macroenvironment, we delivered another strong quarter of results, with improvements in both the top and bottom li

    8/7/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025

    HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to p

    7/24/25 4:05:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova Reports First Quarter 2025 Financial Results

    First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2025. "We delivered strong financial and operational results in the first quarter," said Stephen Gunstream, President and

    5/8/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Telegraph Hill Partners Iv, L.P. bought $14,999,999 worth of shares (12,096,773 units at $1.24) (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/16/24 9:13:16 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Lowell Matthew bought $49,999 worth of shares (40,322 units at $1.24), increasing direct ownership by 46% to 128,376 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/16/24 5:15:21 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Gunstream Stephen bought $100,000 worth of shares (80,645 units at $1.24), increasing direct ownership by 50% to 243,497 units (SEC Form 4)

    4 - Alpha Teknova, Inc. (0001850902) (Issuer)

    7/16/24 5:15:04 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Leadership Updates

    Live Leadership Updates

    View All

    Teknova Announces New Board Member, Martha J. Demski

    HOLLISTER, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the appointment of Martha J. Demski to its Board of Directors, bringing to the Board more than 35 years of experience in corporate leadership and life sciences business and financial strategies. She will replace Robert McNamara, who has served on the Board since Teknova's IPO in 2021 and has announced his intention to step down to pursue other opportunities. Both Ms. Demski's appointment and Mr. McNamara's resignation will be ef

    8/16/23 8:00:00 AM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Financials

    Live finance-specific insights

    View All

    Teknova Reports Second Quarter 2025 Financial Results

    Second quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025. "Despite continued uncertainty in the macroenvironment, we delivered another strong quarter of results, with improvements in both the top and bottom li

    8/7/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025

    HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to p

    7/24/25 4:05:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Teknova Reports First Quarter 2025 Financial Results

    First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2025. "We delivered strong financial and operational results in the first quarter," said Stephen Gunstream, President and

    5/8/25 4:01:00 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TKNO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Alpha Teknova Inc.

    SC 13D - Alpha Teknova, Inc. (0001850902) (Subject)

    7/19/24 4:11:25 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Alpha Teknova Inc. (Amendment)

    SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)

    2/14/24 4:06:12 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Alpha Teknova Inc. (Amendment)

    SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)

    10/6/23 4:10:58 PM ET
    $TKNO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care